Prognostic implications of p21 (Waf1/Cip1) immunolocalization in multiple myeloma

Biomedical Research

Volumn 26, Issue 3, 2005, Pages 91-98

  Ohata, Masahiko ^a,b   Nakamura, Shinobu ^c   Fujita, Hiroyuki ^b   Isemura, Mamoru ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b SHIZUOKA RED CROSS HOSPITAL   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLINE; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CANCER SURVIVAL; CARCINOGENESIS; CASE REPORT; CELL AGING; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE SEVERITY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; MULTIPLE MYELOMA; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

AGED; AGED, 80 AND OVER; HUMANS; IMMUNOHISTOCHEMISTRY; MULTIPLE MYELOMA; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 27244432171     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.26.91     Document Type: Article

References (24)

1. Aoyagi K. Koufuji K. Yano S, Murakami N, Miyagi M, Koga A. Takeda J and Shirouzu K (2003)The expression of p53. p21 and TGF beta 1 in gastric carcinoma. Kurume Med J 50, 1-7.
2. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K and Mizutani S (1999) Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J 18. 1223-1234.
3. Bataille R Grenier J and Sany J (1984) Beta-2 microglobulin in mycloma: optimal use for staging, prognosis, and treatment a prospective study of 160 patients. Blood 63, 468-476.
4. Durie BG and Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, responce to treatment, and survival. Cancer 36, 842-854.
5. Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA, Oken MM, Kay NE, Ness B and Kyle RA (1998) Plasmablastic morphology-an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 Report by the ECOG mycloma laboratory group. Blood 91, 2501-2507.
6. Kanavaros P, Stefanaki K. Vlachonikolis J, Papalazarou D, Rontogianni D, Arvanitis D, Antonakopoulos G, Gorgoulis V, Bai M and Agnantis NJ (2000) Immunohistochemical expression of the p53, p2l/Waf-1, Rb, p16 and Ki67 proteins in multiple myeloma, Anticancer Res 20, 4619-4125.
7. Kirla RM, Haapasalo HK, Kalimo H and Salminen EK (2003) Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas. Cancer 97, 644-648.
8. Korkolopoulou P, Kouzelis K, Christodoulou P, Papanikolaou A and Thomas-Tsagli E (1998) Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: correlations with proliferation markers, p53 expression and survival. Acta Neuropathol (Berlin) 95, 617-624.
9. Lai R, Medeiros LJ, Wilson CS, Sun NC, Koo C. McCourty A and Brynes RK (1998) Expression of the cell-cycle-related proteins E2F-1. p53.mdm-2, p21waf1, and Ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity, Mod Pathol 11, 642-647.
10. Lee HK, Lee HS, Yang HK, Kim WH, Lee KU, Choe KJ and Kim JP (2003) Prognostic significance of Bc1-2 and p53 expression in gastric cancer. Int J Colorectal Dis 18, 518-525.
11. Milde-Langosch K, Hagen M, Bamberger AM and Loning T (2003) Expression and prognostic value of the cell-cycle regulalory proteins, Rb. p16MTS1, p21WAF1, p27K1PI1, cyclin E, and cyclin D2, in ovarian cancer. Int J Gynecol Pathol 22, 168-174.
12. Pappot H, Francis D, Brunner N, Grondahl-Hansen J and Osterlind K (1996) p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: relation to prognosis. Clin Cancer Res 2, 155-160.
13. Pellikainen MJ, Pekola TT, Ropponen KM, Kataja VV Kellokoski JK, Eskelinen MJ and Kosma VM (2003) p21WAF1 expression in invasive breast cancer and its association with p51 AP-2, cell proliferation, and prognosis. J Clin Pathol 56, 214-220.
14. Pescarmona E, Pignoloni P. Puopolo M, Martelli M, Addesso M. Guglielmi C and Baroni CD (2001) p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome. J Pathol 195, 361-366.
15. Pruneri G, Carboni N, Baldini L, Intini D, Colombi M, Bertolini F, Valentini, S, Maisonneuve P, Viale G and Neri A (2003) Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation. Human Pathol 34, 41-47.
16. Rodriguez-Vilarrupla A, Diaz C, Canela N, Rahn HP, Bachs O and Agell N (2002) Identification of the nuclear localization signal of p2l(cip1) and consequences of its mutation on cell proliferation, FEBS Lett 531, 319-323.
17. Schepers H, Geugien M, Eggen BJ and Vellenga E (2003) Constitutive cytolasmic localization of p21(Waf1/Cip1) affects the apoptotic process in monocytic leukaemia. Leukemia 17, 2113-2121.
18. Seo YH, Joo YE, Choi SK, Rew JS, Park CS and Kim SJ (2003) Prognostic significance of p21 and p53 expression in gastric cancer. Korea J Intern; Med 18, 98-103.
19. Shariat SF, Kim J, Raptidis G, Ayala GE and Lerner SP (2003) Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 61, 1140-1145.
20. Tanaka H, Yamashita T, Asada M. Mizutani S, Yoshikawa H and Tohyama M (2002) Cytoplasmic p21(Cip1/WAF1) regulates neurite remodeling by inhibiting Rho-kinase activity. J Cell Biol 158, 321-329.
21. Teoh G, Tai YT, Urashima M, Shirahama S, Matsuzaki M, Chauhan D, Treon SP, Raje N, Hideshima T, Shima Y and, Anderson KC (2000) CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood 95, 1039-1046.
22. Zhang A. Ohshima K. Sato K, Kanda M, Suzumiya J, Shimazaki K, Kawasaki C and Kikuchi M (1999) Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas. Pathol Intern 49, 1043-1052.
23. Zhang W, Grasso L, McClain CD, Gambel AM, Cha Y. Travali S, Deisseroth AB and Mercer WE (1995)p53-independent induction of WAF1/ClP1 in human leukaemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiaton. Cancer Res 55, 668-674.
24. Zhang W, Kornblau SM, Kobayashi T, GAmbel A., Claxton D and Deisseroth AB (1995) High levels of constitutive WAP1/Cip1 protein are associated with chemorcsistance in acute myclogenous leukemia. Clin Cancer Res 1, 1051-1057.